Evaluation of a series of serum mesothelin in patients with pleural Malignant Mesothelioma;Valutazione di dosaggi seriati di mesotelina sierica in pazienti affetti da mesotelioma maligno della pleura

Giornale Italiano di Medicina del Lavoro ed Ergonomia

Volumn 29, Issue 3, 2007, Pages 339-342

  Simonini, S ^a   Foddis, R ^b   Filiberti, R ^c   Puntoni, R ^c   Mutti, L ^d   Ambrosino, N ^a   Chella, A ^a   Guglielmi, G ^a   Buselli, R ^a   Iuzzolini, M ^b   Mignani, A ^a   Ottenga, F ^b   Cristaudo, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d ASL 11 Vercelli

Author keywords

Biological marker; Malignant mesothelioma; Mesothelin

Indexed keywords

MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

AGED; BLOOD; CONFERENCE PAPER; FEMALE; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURA TUMOR;

AGED; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS;

EID: 39349111461     PISSN: 15927830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Sugarbaker DJ: Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol.; 24 (10): 1561-7; 2006.
2. Ricci S, Chioni A et al: Terapia medica del mesotelioma pleurico. Atti del Convegno "Le patologie correlate all'amianto e la sorveglianza sanitaria degli ex-esposti", Pisa 2005.
3. Mutti L et al: Targeted therapy per il mesotelioma pleurico: la realizzazione di un approccio transazionale. Atti del Convegno "Le patologie correlate all'amianto e la sorveglianza sanitaria degli ex-esposti", Pisa 2005.
4. Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet; 362:1612-6; 2003.
5. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res;13: 5076-81; 2007.
6. Scherpereel A et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine; 173: 1155-1160:2006.
7. Hassan R, Remaley AT, Sampson ML, et al: Detection and quantitation of serum mesothelin, a tumor marker for patient with mesothelioma and ovarian cancer. Clin Cancer Res; 12 (2): 447-453; 2006.